Recruiting

Testing immune cells grown from tumors to treat advanced skin cancer

Plain-English translation of NCT07310784 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated September 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new treatment called LM103 TILs for people with advanced melanoma (a serious type of skin cancer) that has spread or come back after other treatments have failed. LM103 TILs is made by taking immune cells from a patient's own tumor, growing more of them in a laboratory, and then putting them back into the patient's body to fight the cancer. The trial will compare this treatment to standard chemotherapy to see which works better.

Many patients with advanced melanoma stop responding to current immunotherapy drugs like checkpoint inhibitors, leaving them with limited options. This medication offers a different approach by using the patient's own immune system in a new way, and researchers hope it may help people whose cancer has become resistant to standard treatments.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced melanoma that cannot be surgically removed or has spread to other parts of your body
your melanoma has failed or you could not tolerate at least two standard treatments, including specific immunotherapy or targeted drugs depending on your tumor type
you have at least one tumor that can be measured and monitored during the study
your overall health and organ function are good enough to tolerate this treatment

You likely don't qualify if…

you have had any other type of cancer in the past 5 years (with some exceptions for very treatable cancers)
you have cancer that has spread to your brain and spine fluid, unless it has been treated and stable for at least 6 months
you have a serious autoimmune disease or an active infection that requires treatment
you have received certain cell therapies in the past 6 months or organ/stem cell transplants
you have serious heart, lung, or liver disease, or untreated infections like hepatitis B, hepatitis C, or HIV

What participation looks like

If you join this trial, you will be randomly assigned to receive either the new cell treatment (LM103 TILs) or standard chemotherapy. To prepare for the cell treatment, doctors will surgically remove a piece of your tumor so they can grow your immune cells in the laboratory — this takes several weeks. You will then receive the treatment and be followed for up to 24 months with regular check-ups to see how well it works and to monitor for any side effects.

AI-generated summary from trial data · Sep 1, 2026 · Not medical advice

Trial locations(16 sites)

China

Beijing Go Broad Hospital, Beijing, Beijing Municipality

Fujian Cancer Hospital, Fuzhou, Fujian

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong

Guangxi Medical University Cancer Hospital, Nanning, Guangxi

The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi